Core Laboratories (HJ1) AI Stock Analysis

1 Followers

Core Laboratories

(Frankfurt:HJ1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Balance-sheet strengtheningMaterial deleveraging and steadily rising equity strengthen Core Lab’s capital base and improve financial flexibility. A lower debt burden should help the company withstand uneven customer activity, preserve funding for technology investment, and support shareholder returns without creating balance-sheet stress.

Negative Factors

Sharp revenue and margin deteriorationThe sharp TTM revenue contraction and lower gross and net margins show weakened operating leverage and reduced earnings power. If demand and pricing do not recover, weaker profitability could constrain reinvestment, reduce returns on capital, and limit the company’s ability to compound cash generation.

Core Laboratories (HJ1) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 414.24M
Dividend Yield: 0.47%
Average Volume (3M): ―
Price to Earnings (P/E): 26.6
Beta (1Y): 0.79
Revenue Growth: -5.05%
EPS Growth: -45.58%
Country: Germany
Employees: 3,300
Sector: Energy
Sector Strength: 65
Industry: Oil & Gas Equipment & Services

Core Laboratories Business Overview & Revenue Model

Company Description

Core Laboratories N.V. (CLB) is a global provider to the oil and gas sector, delivering specialized services and products for characterizing subterranean reservoirs and optimizing hydrocarbon extraction. The company's operations are distinctly segmen...

Core Laboratories Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:-17.58%|Next Earnings Date:Feb 03, 2027

Earnings Call SentimentNeutral

The call was balanced. Core Lab reported meaningful sequential improvements in revenue, operating income, margins, product sales and EPS, along with several technology wins, a 5-year contract and expectations for stronger global activity in 2027. However, geopolitical conflicts continued to depress year-over-year service and Reservoir Description results, reduce demand for crude assay work, delay projects, constrain cash flow and create uncertainty. Fourth-quarter revenue is expected to remain relatively flat, making the overall tone neutral despite management's constructive longer-term outlook.

Positive Updates

Sequential Improvement in Overall Operating Performance

Compared with the second quarter of 2026, operational performance improved with higher revenue, operating income, operating margins and earnings per share.

Negative Updates

Geopolitical Conflicts Continued to Disrupt Operations

The ongoing military conflict in the Middle East, along with escalating attacks on energy infrastructure in Russia and Ukraine and evolving sanctions, caused project delays, logistical disruptions, suspended Middle East field operations and delayed product shipments.

Company Guidance

For the fourth quarter 2026, Core Lab expects revenue to remain relatively flat sequentially; Reservoir Description revenue is projected to range from $81 million to $85 million with operating income of $5.1 million to $8.3 million, Production Enhancement revenue is estimated to range from $47.5 million to $49.5 million with operating income of $5.5 million to $6.7 million, and company revenue is projected to range from $128.5 million to $134.5 million with operating income of $10.7 million to $15.1 million, yielding operating margins of 10%, while EPS is expected to range from $0.12 to $0.20; guidance excludes gains and losses in foreign exchange and assumes an effective tax rate of 25%, 2026 G&A ex-items is expected to be approximately $43 million to $45 million, and full-year 2026 capital expenditures excluding CapEx for rebuilding the U.K. facility are expected to be in the range of $14 million to $16 million.

Core Laboratories Risk Analysis

Core Laboratories disclosed 17 risk factors in its most recent earnings report. Core Laboratories reported the most risks in the "Finance & Corporate" category.

Finance & Corporate5
Tech & Innovation3
Legal & Regulatory2
Production2
Ability to Sell1
Macro & Political4

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Core Laboratories Peers Comparison

Overall Rating

UnderperformOutperform

Sector (65)

Financial Indicators

DE:HJ1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FTI	76Outperform	$25.10B	20.18	38.54%	0.31%	7.95%	42.53%
WFRD	73Outperform	$6.11B	15.40	22.51%	1.27%	-5.65%	0.77%
BKR	66Neutral	$47.44B	16.86	14.83%	1.86%	3.71%	0.14%
HAL	66Neutral	$26.35B	13.78	18.46%	2.06%	1.53%	58.46%
Sector *	65Neutral	$15.17B	7.61	4.09%	5.20%	3.87%	-62.32%
XPRO	58Neutral	$1.47B	1152.99	0.10%	―	-4.75%	-97.74%

* Energy Sector Average

Performance Comparison

DE:HJ1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:HJ1	Core Laboratories N.V.	7.45	-5.21	-41.13%
BKR	Baker Hughes Company	49.41	2.63	5.63%
FTI	TechnipFMC	65.39	22.37	52.00%
HAL	Halliburton Company	32.93	6.45	24.34%
WFRD	Weatherford International Plc	86.69	15.30	21.42%
XPRO	Expro Group Holdings N.V.	13.49	0.04	0.30%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Core Laboratories AI Stock Analysis